Latest Commercial Expansion News

Algorae Pharmaceuticals has signed a binding term sheet with India’s Cadila Pharmaceuticals to introduce two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand.

Compumedics has secured a $2.15 million placement to fast-track commercialisation of its Somfit D device following early FDA approval, positioning the company for significant growth in the US home sleep testing market.

Latrobe Magnesium Limited (ASX – LMG) has launched an $8 million equity raising to fund the ramp-up of its magnesium metal production and advance feasibility studies for a larger commercial plant. The company’s patented hydromet process converts brown coal ash into sustainable magnesium with significantly lower emissions than global peers.

Orthocell Limited has reported a record $3 million quarterly revenue, driven by strong sales of its nerve repair product Remplir in Australia and Singapore, while advancing its rollout in the US and Canada ahead of schedule.

4DMedical has secured $22.6 million through the exercise of deep in-the-money options, significantly strengthening its cash position to support the commercial rollout of its CT – VQ™ respiratory imaging technology.

Orthocell has reported a record $3 million revenue for the September quarter, driven by strong sales of its nerve repair product Remplir™ in Australia and Singapore, with early US sales and Canadian market entry poised to accelerate growth.

CurveBeam AI has secured A$6.5 million through an institutional placement and completed a €10 million vendor financing facility to accelerate sales of its HiRise™ CT scanner. The company is also progressing a strategic partnership in China and advancing surgical robot validation.

Algorae Pharmaceuticals has secured an exclusive licensing agreement with Sakar Healthcare to introduce five generic oncology medicines in Australia and New Zealand, marking its first commercial foray in the region.

Adherium Limited’s iCARE study reports unprecedented medication adherence improvements and sustained patient engagement in COPD and asthma care, highlighting significant clinical and economic benefits.

InteliCare Holdings has raised $2 million through a two-tranche placement to accelerate its AI-driven aged care platform and terminated a convertible note facility to streamline its capital base.

Artrya Limited has raised A$75 million through a two-tranche placement and launched a A$5 million share purchase plan to fast-track the U.S. commercialisation of its AI-powered Salix platform following FDA clearance.

Proteomics International Laboratories announces the planned retirement of its founder and Managing Director, Dr Richard Lipscombe, in February 2026, marking a pivotal leadership transition as the company seeks a new CEO to drive its next growth phase.